An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

about

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.

P2860

Q33737587-C0FBA4C3-7618-478B-B9C2-9DEDB7682312

P2860

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

Item

http://www.wikidata.org/entity/Q38835123

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

@en

type

Item

label

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

@en

prefLabel

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

@en

P1476

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

@en

P2093

Enrique Grande

http://www.w3.org/2001/XMLSchema#string

Javier Molina

http://www.w3.org/2001/XMLSchema#string

Juan José Díez

http://www.w3.org/2001/XMLSchema#string

Olga Martínez-Sáez

http://www.w3.org/2001/XMLSchema#string

Pablo Reguera

http://www.w3.org/2001/XMLSchema#string

Teresa Alonso-Gordoa

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

Gastroenteropancreatic high-grade neuroendocrine carcinoma

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Rationale for the use of somatostatin analogs as antitumor agents

A quantitative analysis of kinase inhibitor selectivity

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

P304

13-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40487-015-0007-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282539456

http://www.w3.org/2001/XMLSchema#string

P698

27182476

http://www.w3.org/2001/XMLSchema#string

P932

4837935

http://www.w3.org/2001/XMLSchema#string

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

about

P2860

P2860

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932